Immune Resetting: B-Cell Mediated and Beyond

The era of blanket immunosuppression is ending. A new chapter in autoimmune therapy is unfolding, one where precision replaces broad suppression, and immune resetting takes centre stage. B-cell depletion therapies have paved the way, but the question remains: what's next?
 
 
Innovations such as cell therapy, T-cell engagers, bispecifics, and next-generation monoclonal antibodies are no longer distant possibilities, they're here, poised to redefine treatment paradigms. What was once blue-sky thinking is now becoming a reality, fueled by major investments and strategic acquisitions like Kite Pharma's move for Interius Biotherapeutics and AbbVie's acquisition of Capstan. Rising interest in targets such as BCMA for lupus nephritis signals a seismic shift toward curative potential.
 
 
Harnessing this energy, the inaugural Immune Resetting: B-Cell Mediated and Beyond Summit launches at this pivotal moment, uniting biopharma leaders, academic KOLs, and immunology innovators to accelerate progress. From discovery through clinical application, this is your opportunity to benchmark strategies, build partnerships, and take actionable insights back to your programs.
 
 
Join 50+ experts to explore how targeted interventions can recalibrate the immune system, delivering durable, transformative therapies for lupus, systemic sclerosis, rheumatoid arthritis, multiple sclerosis, and beyond. The future of autoimmune care is being written and you should be a part of it.